SVB Wealth LLC Has $175,000 Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

SVB Wealth LLC decreased its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 9.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 12,235 shares of the company’s stock after selling 1,326 shares during the period. SVB Wealth LLC’s holdings in Takeda Pharmaceutical were worth $175,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of TAK. SG Americas Securities LLC increased its holdings in shares of Takeda Pharmaceutical by 73.1% during the third quarter. SG Americas Securities LLC now owns 16,043 shares of the company’s stock worth $248,000 after buying an additional 6,775 shares in the last quarter. Caprock Group LLC increased its holdings in shares of Takeda Pharmaceutical by 17.3% during the third quarter. Caprock Group LLC now owns 67,276 shares of the company’s stock worth $1,041,000 after buying an additional 9,906 shares in the last quarter. Aaron Wealth Advisors LLC increased its holdings in shares of Takeda Pharmaceutical by 39.2% during the third quarter. Aaron Wealth Advisors LLC now owns 18,403 shares of the company’s stock worth $285,000 after buying an additional 5,185 shares in the last quarter. Simplicity Solutions LLC increased its holdings in shares of Takeda Pharmaceutical by 0.4% during the third quarter. Simplicity Solutions LLC now owns 213,515 shares of the company’s stock worth $3,303,000 after buying an additional 955 shares in the last quarter. Finally, Ballentine Partners LLC grew its stake in shares of Takeda Pharmaceutical by 47.3% during the third quarter. Ballentine Partners LLC now owns 19,968 shares of the company’s stock valued at $309,000 after purchasing an additional 6,412 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Price Performance

TAK opened at $13.39 on Wednesday. Takeda Pharmaceutical Company Limited has a one year low of $13.11 and a one year high of $17.11. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.06 and a quick ratio of 0.55. The company’s 50 day simple moving average is $14.14 and its 200-day simple moving average is $14.23. The stock has a market capitalization of $42.36 billion, a P/E ratio of 20.28, a price-to-earnings-growth ratio of 3.78 and a beta of 0.53.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The business had revenue of $7.52 billion for the quarter. Sell-side analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.5 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.